WO2013084151A3 - Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 - Google Patents

Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 Download PDF

Info

Publication number
WO2013084151A3
WO2013084151A3 PCT/IB2012/056956 IB2012056956W WO2013084151A3 WO 2013084151 A3 WO2013084151 A3 WO 2013084151A3 IB 2012056956 W IB2012056956 W IB 2012056956W WO 2013084151 A3 WO2013084151 A3 WO 2013084151A3
Authority
WO
WIPO (PCT)
Prior art keywords
her3
domain
antibodies
directed
growth factor
Prior art date
Application number
PCT/IB2012/056956
Other languages
French (fr)
Other versions
WO2013084151A2 (en
Inventor
Winfried Elis
Seth Ettenberg
Andrew Paul Garner
Nicole Haubst
Heather Huet
Christian Carsten Silvester KUNZ
Elizabeth Anne REISINGER SPRAGUE
Qing SHENG
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2014006731A priority Critical patent/MX2014006731A/en
Priority to CA2857939A priority patent/CA2857939A1/en
Priority to BR112014013495A priority patent/BR112014013495A8/en
Priority to AU2012349739A priority patent/AU2012349739A1/en
Priority to EA201491120A priority patent/EA201491120A1/en
Priority to EP12816130.4A priority patent/EP2788381A2/en
Priority to JP2014545420A priority patent/JP2015500830A/en
Priority to CN201280068966.8A priority patent/CN104093742A/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to SG11201402784WA priority patent/SG11201402784WA/en
Priority to KR1020147018336A priority patent/KR20140099315A/en
Priority to IN4374CHN2014 priority patent/IN2014CN04374A/en
Publication of WO2013084151A2 publication Critical patent/WO2013084151A2/en
Publication of WO2013084151A3 publication Critical patent/WO2013084151A3/en
Priority to IL232950A priority patent/IL232950A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to antibodies or fragments thereof that bind to a non-linear epitope within domain 3 of the HER3 receptor and inhibit both ligand-dependent and ligand-independent signal transduction. The invention also relates antibodies or fragments thereof that bind to amino acid residues within domains 3-4 of HER3 and inhibit both ligand-dependent and ligand-independent signal transduction; and compositions and methods of use of such antibodies or fragments thereof.
PCT/IB2012/056956 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 WO2013084151A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2014545420A JP2015500830A (en) 2011-12-05 2012-12-04 HER3 antibody against domain III and domain IV of epidermal growth factor receptor 3 (HER3)
BR112014013495A BR112014013495A8 (en) 2011-12-05 2012-12-04 antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain iv
AU2012349739A AU2012349739A1 (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain III and domain IV of HER3
EA201491120A EA201491120A1 (en) 2011-12-05 2012-12-04 ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH FACTOR 3 (HER3), DIRECTED TO DOMAIN III AND DOMAIN IV HER3
EP12816130.4A EP2788381A2 (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
MX2014006731A MX2014006731A (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3.
CN201280068966.8A CN104093742A (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain III and domain IV of her3
CA2857939A CA2857939A1 (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
SG11201402784WA SG11201402784WA (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
KR1020147018336A KR20140099315A (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
IN4374CHN2014 IN2014CN04374A (en) 2011-12-05 2012-12-04
IL232950A IL232950A0 (en) 2011-12-05 2014-06-02 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566912P 2011-12-05 2011-12-05
US61/566,912 2011-12-05

Publications (2)

Publication Number Publication Date
WO2013084151A2 WO2013084151A2 (en) 2013-06-13
WO2013084151A3 true WO2013084151A3 (en) 2014-01-03

Family

ID=47561692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/056956 WO2013084151A2 (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3

Country Status (16)

Country Link
EP (1) EP2788381A2 (en)
JP (1) JP2015500830A (en)
KR (1) KR20140099315A (en)
CN (1) CN104093742A (en)
AR (1) AR089085A1 (en)
AU (1) AU2012349739A1 (en)
BR (1) BR112014013495A8 (en)
CA (1) CA2857939A1 (en)
EA (1) EA201491120A1 (en)
IL (1) IL232950A0 (en)
IN (1) IN2014CN04374A (en)
MX (1) MX2014006731A (en)
SG (1) SG11201402784WA (en)
TW (1) TW201331225A (en)
UY (1) UY34488A (en)
WO (1) WO2013084151A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7358256B2 (en) 2014-02-28 2023-10-10 メルス ナムローゼ フェンノートシャップ pharmaceutical composition

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941030A1 (en) 2014-02-28 2015-09-03 Merus N.V. Antibodies that bind egfr and erbb3
JP6755235B2 (en) 2014-07-16 2020-09-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Inhibition of HER3 in low-grade serous cancer
CN104530237B (en) * 2014-12-31 2017-09-05 百泰生物药业有限公司 Anti- Her1 therapeutic antibodies
CN108602888B (en) 2015-10-23 2022-10-04 美勒斯公司 Binding molecules that inhibit cancer growth
JP6729926B2 (en) * 2016-05-12 2020-07-29 国立大学法人神戸大学 ErbB3 activation signal transduction inhibitor and method for screening the same
WO2018050848A1 (en) * 2016-09-15 2018-03-22 Universität Stuttgart Antigen binding protein against her3
KR101923641B1 (en) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 Anti-HER3 antibody and composition for preventing or treating cancer comprising the same
MX2019011660A (en) 2017-03-31 2019-11-18 Merus Nv Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene.
MA49846A (en) 2017-08-09 2020-06-17 Merus Nv ANTIBODIES THAT BOUND TO EGFR AND CMET

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077028A2 (en) * 2005-12-30 2007-07-12 U3 Pharma Ag Antibodies directed to her-3 and uses thereof
WO2010127181A1 (en) * 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
WO2011060206A2 (en) * 2009-11-13 2011-05-19 U3 Pharma Gmbh Material and methods for treating or preventing her-3 associated diseases
WO2011136911A2 (en) * 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
WO2012031198A2 (en) * 2010-09-03 2012-03-08 Glaxo Group Limited Novel antigen binding proteins
WO2012156309A1 (en) * 2011-05-13 2012-11-22 Millegen Antibodies against her3
WO2013016714A1 (en) * 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077028A2 (en) * 2005-12-30 2007-07-12 U3 Pharma Ag Antibodies directed to her-3 and uses thereof
WO2010127181A1 (en) * 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
WO2011060206A2 (en) * 2009-11-13 2011-05-19 U3 Pharma Gmbh Material and methods for treating or preventing her-3 associated diseases
WO2011136911A2 (en) * 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
WO2012031198A2 (en) * 2010-09-03 2012-03-08 Glaxo Group Limited Novel antigen binding proteins
WO2012156309A1 (en) * 2011-05-13 2012-11-22 Millegen Antibodies against her3
WO2013016714A1 (en) * 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G SALA ET AL: "An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling", ONCOGENE, vol. 31, no. 10, 8 August 2011 (2011-08-08), pages 1275 - 1286, XP055042235, ISSN: 0950-9232, DOI: 10.1038/onc.2011.322 *
GABRIELE SCHAEFER ET AL: "A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies", CANCER CELL, CELL PRESS, US, vol. 20, no. 4, 18 October 2011 (2011-10-18), pages 472 - 486, XP002679896, ISSN: 1535-6108, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/S1535610811003515> [retrieved on 20111017], DOI: 10.1016/J.CCR.2011.09.003 *
GABRIELE SCHAEFER ET AL: "SUPPLEMENTAL INFORMATION - A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies", CANCER CELL, CELL PRESS, US, vol. 20, no. 4, 9 September 2011 (2011-09-09), pages S1 - S21, XP002709668, ISSN: 1535-6108, [retrieved on 20110915], DOI: 10.1016/J.CCR.2011.09.003 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7358256B2 (en) 2014-02-28 2023-10-10 メルス ナムローゼ フェンノートシャップ pharmaceutical composition

Also Published As

Publication number Publication date
IL232950A0 (en) 2014-07-31
JP2015500830A (en) 2015-01-08
AU2012349739A1 (en) 2014-06-26
BR112014013495A2 (en) 2017-06-13
KR20140099315A (en) 2014-08-11
SG11201402784WA (en) 2014-06-27
WO2013084151A2 (en) 2013-06-13
UY34488A (en) 2013-07-31
AR089085A1 (en) 2014-07-30
CA2857939A1 (en) 2013-06-13
MX2014006731A (en) 2015-06-04
EP2788381A2 (en) 2014-10-15
TW201331225A (en) 2013-08-01
CN104093742A (en) 2014-10-08
BR112014013495A8 (en) 2017-06-13
IN2014CN04374A (en) 2015-09-04
EA201491120A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
WO2013084151A3 (en) Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
WO2013084148A3 (en) Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
MY162825A (en) Antibodies for epidermal growth factor receptor 3 (her3)
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
WO2013041844A3 (en) Antibodies, variable domains &amp; chains tailored for human use
MX350957B (en) Binding molecules specific for her3 and uses thereof.
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
WO2011123489A3 (en) Anti-cd40 antibodies
WO2009002380A3 (en) Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
MX353706B (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use.
MX346486B (en) Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies.
WO2011130377A3 (en) Amyloid-beta binding proteins
GEP20125612B (en) Prlr-specific antibody and usage thereof
WO2011004028A3 (en) Tlr3 binding agents
UA106070C2 (en) Antibody that specifically binds to egfr and her3
HRP20180563T1 (en) Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
UY32914A (en) ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
WO2011098552A3 (en) Methods and compositions for the preparation of aerosols
JO3437B1 (en) Improved anti human Fraktalkine antibodies and uses thereof
WO2015048008A3 (en) Binding molecules specific for her3 and uses thereof
EP2546269B8 (en) Monoclonal antibody against necrosis marker prdx4 and use thereof
WO2012028958A3 (en) Antibody for colorectal cancer marker
IL208188A0 (en) Compositions comprising antibodies or antibody fragments

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2857939

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 232950

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2014545420

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/006731

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2012816130

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012349739

Country of ref document: AU

Date of ref document: 20121204

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147018336

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201491120

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12816130

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014013495

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014013495

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140604